Biotherapy : is there potential for technological platforms ?
Oct 10, 2024 | 9:45 AM CEST - 10:15 AM CESTBULLE LA FRENCH CARE
Oct 10, 2024 | 9:45 AM CEST - 10:15 AM CEST
BULLE LA FRENCH CARE
Description
If part of biotech firms are "mono-product", others are developing their own technological platforms, which allows them to bring about different drug candidates. This model combines certain advantages and a particular complexity. What is the ideal development strategy to implement for POC validation ? What should you choose as a first indicator ? How can you guarantee a coherent portfolio in regards to the different developed assets ?
